KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Receivables (2016 - 2025)

Abbott Laboratories' Receivables history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • For Q4 2025, Receivables rose 14.5% year-over-year to $7.9 billion; the TTM value through Dec 2025 reached $7.9 billion, up 14.5%, while the annual FY2025 figure was $7.9 billion, 14.5% up from the prior year.
  • Receivables for Q4 2025 was $7.9 billion at Abbott Laboratories, down from $8.1 billion in the prior quarter.
  • Across five years, Receivables topped out at $8.1 billion in Q3 2025 and bottomed at $6.0 billion in Q1 2023.
  • The 5-year median for Receivables is $6.6 billion (2023), against an average of $6.8 billion.
  • The largest annual shift saw Receivables rose 18.93% in 2021 before it fell 16.14% in 2023.
  • A 5-year view of Receivables shows it stood at $6.5 billion in 2021, then decreased by 4.15% to $6.2 billion in 2022, then rose by 5.58% to $6.6 billion in 2023, then increased by 5.48% to $6.9 billion in 2024, then rose by 14.5% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Receivables are $7.9 billion (Q4 2025), $8.1 billion (Q3 2025), and $8.0 billion (Q2 2025).